Chronicle Journal: Finance

Zai Lab Says HER2 Drug Meets Endpoints in Bridging Trial

Shanghai 's Zai Lab reported its in-licensed HER2 drug met its endpoints in patients with previously treated HER2+ breast cancer. Zai acquired China rights to margetuximab as part of a $165 million, three-drug deal from MacroGenics in 2018. MacroGenics was approved to launch margetuximab in the US last year in combination with chemotherapy as a third-line treatment for HER2 positive breast cancer. Zai plans to file a BFA in China before the end of the year. More details.... Stock Symbols: (NSDQ: ZLAB; HKEX: 9688) (NSDQ: MGNX) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.